Recent Analysts' Ratings Changes for Gilead Sciences

Recent Analysts' Ratings Changes for Gilead Sciences


They now have a $84.00 price target on the stock. According to Zacks, "Gilead reported better-than-expected results for the second quarter driven by positive trends in the non-HCV business and improved results from HCV business due to rapid uptake of Epclusa.



from Biotech News